Capital markets·October 23, 2026 at 11:58 AM EDT·1 source
Food Allergy Biotech Firm Lycia Jumps 32% After Upsized IPO
LYCA
ipo, log scale$318M
$100M$1B$10B$100B
What happened
- Lycia Therapeutics shares rose 32% in their trading debut.
- The biotechnology company focuses on treatments for allergies and autoimmune diseases.
- Lycia raised $317.5 million in an upsized US initial public offering.
Trading debut gain
32%
IPO proceeds
$317.5 million
Why it matters
The IPO provides a sizable public-market financing for a biotech focused on allergy and autoimmune treatments, relevant to healthcare investors and ECM professionals.
Deal terms
ipo
Lycia Therapeutics Inc.
Value
$318M
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Sources (1)
- BloombergOct 23Food Allergy Biotech Firm Lycia Jumps 32% After Upsized IPO
Related
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.